pharma · COVID-19 · Cystic Fibrosis · ARCT
Arcturus Therapeutics
Arcturus Therapeutics Holdings
Arcturus Therapeutics clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 10285 Science Center Dr, San Diego, California 92121, US
- Founded
- 2013
- Employees
- 157
- Programs
- 13
- Drugs
- 7
- Patents
- 55
Arcturus Therapeutics projects
9 ClinicalTrials.gov programs sponsored by Arcturus Therapeutics.
Arcturus Therapeutics has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
ARCT-021
Arcturus Therapeutics Holdings
SARS-CoV-2
1 trial -
ARCT-021 Dose 1
Arcturus Therapeutics Holdings
SARS-CoV-2
1 trial -
ARCT-021 single dose priming
Arcturus Therapeutics Holdings
Covid19
1 trial -
ARCT-032
Arcturus Therapeutics Holdings
Cystic Fibrosis
2 trials -
ARCT-032-02
Arcturus Therapeutics Holdings
Cystic Fibrosis
1 trial -
ARCT-165
Arcturus Therapeutics Holdings
COVID-19
1 trial -
ARCT-810
Arcturus Therapeutics Holdings
Ornithine Transcarbamylase Deficiency
3 trials -
ARCT-810
Arcturus Therapeutics Holdings
OTC Deficiency
1 trial -
SARS-CoV-2 mRNA Vaccine ARCT-021
Arcturus Therapeutics Holdings
Hematopoietic and Lymphatic System Neoplasm
1 trial
Frequently asked questions
How many clinical projects does Arcturus Therapeutics have?
9 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.